tilray
Global pharmaceutical medical cannabis company Tilray Inc (NASDAQ:TLRY) experienced extraordinary volatility towards the end of last week with shares rallying 30.8% on Thursday to $3.90 following commentary from President Biden before erasing most gains and falling -18.7% on Friday after releasing first quarter results with the stock closing at $3.17. Tilray, along with the rest of the Cannabis sector received a boost of investor buying after President Joe Biden on Thursday announced that he had pardoned all people formerly convicted of federal marijuana possession. Tilray rose as high as $3.9...
ValueWalk
Tilray (TLRY) stock jumps on strong earnings and an expanded addressable market Following a torrential implosion of market value since February last year, cannabis firm Tilray (NASDAQ:TLRY, TSE:TLRY) finally gave its stakeholders a reason to smile. Management reported encouraging developments for its fiscal year 2022, including double-digit revenue growth and expectations to be cash flow positive in FY 2023. Further, Switzerland legalizing medical marijuana theoretically expands the total addressable market for cannabis companies. Tilray in particular specializes in exploring the therapeutic p...
ValueWalk
Information about the bill, analyst commentary and a popular weed stock with retail investors Cannabis Stocks RiseCannabis stocks rose Thursday after Bloomberg reported that Senate Democrats plan to introduce legislation decriminalizing the popular and widespread plant’s use. The report said Senate Majority Leader Chuck Schumer and fellow democrats Cory Booker and Ron Wyden planned to introduce the Cannabis Administration and Opportunity Act. Q2 2022 hedge fund letters, conferences and more That sent weed stocks across the US and Canada higher with welcome relief after widespread losses that h...
ValueWalk
Medical and consumer cannabis producer Tilray (NASDAQ:TLRY) stock has been an abysmal performer as shares collapsed to a low of $4.78 from its high of $300 after its IPO in September of 2018. The speculation of federal marijuana legalization and profitability initially drove up shares, but the reality of neither occurring for three-years has caused shares to deflate. Incidentally, the Company surprised investors by reporting a profit in its latest earnings report as the pursuit of federal legalization receives another push. Tilray was successful in reaching its target $80 million in synergies ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら